Oligodendroglioma classification
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma classification On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma classification |
|
Risk calculators and risk factors for Oligodendroglioma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
Oligodendroglioma may be classified according to the WHO classification of the central nervous system tumors into five subtypes: oligodendroglioma (OII), anaplastic oligodendroglioma (OIII), oligoastrocytoma (OAII), anaplastic oligoastrocytoma (OAIII), and glioblastoma with oligodendroglioma component (GBMo).
Classification
- As of the 2016 edition of the WHO classification, gliomas are classified based not only on histopathologic appearance but also on well-established molecular parameters
- As of the 2016 update of the World Health Organization (WHO) classification of central nervous system tumors, oligodendroglial tumors are now more narrowly defined by molecular diagnostics to include only those diffuse gliomas harboring both a mutation in isocitrate dehydrogenase type 1 (IDH1) or type 2 (IDH2) and codeletion of chromosomes 1p and 19q.
| Tumor classification | Tumor grade | Defining* or characteristic molecular genetic features |
|---|---|---|
| Astrocytic tumors | ||
| Diffuse astrocytoma, IDH-mutant | II | IDH1/2 mutation*, TP53 mutation, ATRX mutation |
| Diffuse astrocytoma, IDH-wildtype | II | No IDH1/2 mutation |
| Anaplastic astrocytoma, IDH-mutant | III | IDH1/2 mutation*, TP53 mutation, ATRX mutation |
| Anaplastic astrocytoma, IDH-wildtype | III | No IDH1/2 mutation |
| Glioblastoma, IDH-mutant | IV | IDH1/2 mutation*, TP53 mutation, ATRX mutation |
| Glioblastoma, IDH-wildtype | IV | No IDH1/2 mutation, TERT promoter mutations |
| Glioblastoma, NOS | IV | Genetic testing not done or inconclusive |
| Midline diffuse glioma, H3 K27M-mutant | IV | H3 K27M mutation* |
| Oligodendroglial tumors | ||
| Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | II | IDH1/2 mutation*, 1p/19q-codeletion*, no ATRX mutation, TERTpromoter mutations |
| Oligodendroglioma, NOS | II | Genetic testing not done or inconclusive |
| Oligoastrocytoma, NOS | II | Genetic testing not done or inconclusive |
| Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted | III | IDH1/2 mutation*, 1p/19q-codeletion*, no ATRX mutation, TERTpromoter mutations |
| Anaplastic oligodendroglioma, NOS | III | Genetic testing not done or inconclusive |
| Anaplastic oligoastrocytoma, NOS | III | Genetic testing not done or inconclusive |
IDH: isocitrate dehydrogenase; NOS: not otherwise specified
* Alterations that define the WHO classification entity are marked by an asterisk
Data from: WHO classification of tumours of the central nervous system, revised 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016
- Oligodendroglioma may be classified according to the 2007 WHO classification of the central nervous system tumors into five subtypes:[1]
WHO classification of tumors of CNS | |||||||||||||||||||||||||||||||||||||||||||||
WHO grade II | WHO grade III | WHO grade IV | |||||||||||||||||||||||||||||||||||||||||||
Oligodendroglioma (OII) | |||||||||||||||||||||||||||||||||||||||||||||
Reference
- ↑ Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A; et al. (2007). "The 2007 WHO classification of tumours of the central nervous system". Acta Neuropathol. 114 (2): 97–109. doi:10.1007/s00401-007-0243-4. PMC 1929165. PMID 17618441.